Mattiasson A - Search Results

1

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.

Zinner NR, Mattiasson A, Stanton SL. Zinner NR, et al. Among authors: mattiasson a. J Am Geriatr Soc. 2002 May;50(5):799-807. doi: 10.1046/j.1532-5415.2002.50203.x. J Am Geriatr Soc. 2002. PMID: 12028164 Clinical Trial.

2

Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, van Kerrebroeck P; International Continence Society. Schäfer W, et al. Among authors: mattiasson a. Neurourol Urodyn. 2002;21(3):261-74. doi: 10.1002/nau.10066. Neurourol Urodyn. 2002. PMID: 11948720

3

Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.

Mattiasson A, Blaakaer J, Høye K, Wein AJ; Tolterodine Scandinavian Study Group. Mattiasson A, et al. BJU Int. 2003 Jan;91(1):54-60. doi: 10.1046/j.1464-410x.2003.03076.x. BJU Int. 2003. PMID: 12614251 Clinical Trial.

4

Management of overactive bladder--looking to the future.

Mattiasson A. Mattiasson A. Urology. 1997 Dec;50(6A Suppl):111-3. doi: 10.1016/s0090-4295(97)00605-5. Urology. 1997. PMID: 9426765

5

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Abrams P, Freeman R, Anderström C, Mattiasson A. Abrams P, et al. Among authors: mattiasson a. Br J Urol. 1998 Jun;81(6):801-10. doi: 10.1046/j.1464-410x.1998.00717.x. Br J Urol. 1998. PMID: 9666761 Clinical Trial.

6

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.

Mattiasson A, Masala A, Morton R, Bolodeoku J; SOLAR Study Group. Mattiasson A, et al. BJU Int. 2010 Apr;105(8):1126-35. doi: 10.1111/j.1464-410X.2009.08910.x. Epub 2009 Oct 10. BJU Int. 2010. PMID: 19818077 Clinical Trial.

7

Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model.

Kobelt G, Jönsson L, Mattiasson A. Kobelt G, et al. Among authors: mattiasson a. Neurourol Urodyn. 1998;17(6):599-611. doi: 10.1002/(sici)1520-6777(1998)17:6<599::aid-nau4>3.0.co;2-j. Neurourol Urodyn. 1998. PMID: 9829424

8

Effects of pinacidil on detrusor instability in men with bladder outlet obstruction.

Hedlund H, Mattiasson A, Andersson KE. Hedlund H, et al. Among authors: mattiasson a. J Urol. 1991 Nov;146(5):1345-7. doi: 10.1016/s0022-5347(17)38087-4. J Urol. 1991. PMID: 1942288 Clinical Trial.

9

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.

Stahl MM, Ekström B, Sparf B, Mattiasson A, Andersson KE. Stahl MM, et al. Among authors: mattiasson a. Neurourol Urodyn. 1995;14(6):647-55. doi: 10.1002/nau.1930140606. Neurourol Urodyn. 1995. PMID: 8750383

10

Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Mattiasson A, et al. BJU Int. 2002 Jun;89(9):855-62. doi: 10.1046/j.1464-410x.2002.02791.x. BJU Int. 2002. PMID: 12010228 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters